ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
ICU Medical reported Q2 revenue of $551.7 million, up 1% year-over-year on a GAAP basis, with non-GAAP organic revenue growing 6%. Profitability improved significantly as GAAP gross margin expanded to 43% from 38% in the prior year, driving Adjusted EPS to $2.37.
Key figures
- Eps
- 0.76
- Revenue
- 551700000
- Guidance
- FY26 Adjusted EPS $8.60-$9.00 (raised from $7.75-$8.45); GAAP EPS $2.89-$3.29 (raised from $1.03-$1.74); Adjusted EBITDA $415M-$435M (raised from $400M-$430M)
- Revenue Yoy
- 1%
- Adjusted eps
- 2.37
- Free cash flow
- 61660000
- Adjusted ebitda
- 110000000
- Gaap gross margin
- 43%
- Organic revenue growth
- 6%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.